Ignite Creation Date:
2025-12-25 @ 12:04 AM
Ignite Modification Date:
2026-03-13 @ 8:40 AM
Study NCT ID:
NCT00366158
Status:
COMPLETED
Last Update Posted:
2019-02-04
First Post:
2006-08-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
EVITA: Evaluation of VIP Feature in Pacemaker Patients
Sponsor:
Abbott Medical Devices
Organization:
Study Overview
Official Title:
EVITA: Evaluation of VIP Feature in Pacemaker Patients
Status:
COMPLETED
Status Verified Date:
2019-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary efficacy objective of this clinical investigation is to demonstrate that the Ventricular Intrinsic Preference (VIP™) feature allows to reduce the medium- and long-term incidence of unnecessary ventricular pacing in patients with intact AV conduction.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: